REG - Abingdon Health PLC - Director/PDMR Shareholding

Abingdon HealthAnnouncement

26/09/2022 13:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220926:nRSZ6693Aa&default-theme=true

RNS Number : 6693A  Abingdon Health PLC  26 September 2022

Abingdon Health plc

("Abingdon" or "the Company")

 

Director/PDMR Dealing

 

York, U.K. 26 September 2022: Abingdon Health plc (AIM: ABDX), a leading
international developer and manufacturer of high quality and effective rapid
tests, announces that, in addition to the Director Dealing announced on 16
September 2023
(https://polaris.brighterir.com/public/abingdon_health/news/rns/story/w6zdykr
(https://polaris.brighterir.com/public/abingdon_health/news/rns/story/w6zdykr)
), on 23 September 2022, Chris Yates, Chief Executive Officer purchased a
total of 125,000 ordinary shares of 0.25 pence each ("Ordinary Shares") over
two trades (the "Purchases") at a price of 7.3 pence per Ordinary Share.
Further to the Purchases, the interest of Chris Yates in the Company is as
follows:

 

 Director     Previous number of Ordinary Shares held  Number of Ordinary Shares Purchased  Number of Ordinary Shares held following Purchases  Percentage of Ordinary Shares held following Purchases
 Chris Yates  7,763,844                                125,000                              7,888,844                                           6.48%

 

Concert Party

 

Further to the disclosures in the Company's Admission Document published 11
December 2020 ("Admission Document"), Chris Yates is a member of a concert
party (the "Concert Party"). As a result of the Purchases, the aggregate
number of Ordinary Shares held by the Concert Party has increased from
42,861,888 to 42,986,888, representing an increase from 35.21 per cent. to
35.32 per cent. of the issued share capital of the Company.

 

The Purchases were effected under the terms of Note 11 on Rule 9.1 of the Code
and therefore have no consequences under the Takeover Code.

 

As set out in the Company's Admission Document, Chris Yates also holds 392,695
options over Ordinary Shares. It was agreed with the Panel prior to the
Company's initial public offering that an obligation under Rule 9 will not
arise as a result of the issue of new Ordinary Shares to members of the
Concert Party following the exercise of those options referred to above,
without the requirement to seek the approval of independent shareholders.

 

The Concert Party could therefore come to hold in aggregate up to 43,379,513
Ordinary Shares (following the exercise of all options held by its members
only), representing a maximum potential interest of up to 35.64 per cent. of
the enlarged share capital (as enlarged by such exercise).

 

Details of the transactions undertaken can be found in the Notification of
Dealing Form below.

Enquiries:

 

 Abingdon Health plc                                                                   www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer                                                  Via Walbrook PR
 Melanie Ross, Chief Financial Officer
 Dr Chris Hand, Non-Executive Chairman

 Singer Capital Markets (Sole Broker and Nominated Adviser)                            Tel: +44 (0)20 7496 3000
 Peter Steel, Alex Bond, Sam Butcher (Corporate Finance)
 Tom Salvesen (Corporate Broking)

 Walbrook PR Limited                                      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                                          (mailto:abingdon@walbrookpr.com)
 Phillip Marriage / Alice Woodings  Mob: +44 (0)7867 984 082 / +44 (0)7407 804 654

 

 

 

 

About Abingdon Health plc

 

Abingdon Health is a world leading developer and manufacturer of
high-quality lateral flow rapid tests
(https://www.abingdonhealth.com/services/)  across all industry sectors,
including healthcare and COVID-19. Abingdon is the partner of choice for a
growing global customer base and takes projects from initial concept through
to routine and large-scale manufacturing and has also developed and marketed
its own labelled tests.

 

The Company offers product development, regulatory support, technology
transfer and manufacturing services for customers looking to develop new
assays or transfer existing laboratory-based assays to a lateral flow
format. Abingdon Health aims to support the increase in need for rapid
results across many industries and locations and produces lateral flow tests
in areas such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access to results
allows for rapid decision making, targeted intervention and can support better
outcomes. This ability has a significant role to play in improving life across
the world. To support this aim Abingdon Health has also developed AppDx(®),
a customisable image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

.

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Chris Yates

 2    Reason for the notification

 a)   Position/status                                              Chief Executive Officer

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Abingdon Health plc

 b)   LEI                                                          213800XFI4WV3FBILO20

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.025 pence each

      Identification code                                          GB00BLF79J41

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                   Price(s)             Volume(s)
                                                                                   7.3 pence            50,000
                                                                                   7.3 pence            75,000

 d)   Aggregated information                                                       Total volume: 125,000 Ordinary Shares

                                                                                   Price: 7.3 pence per Ordinary Share

 e)   Date of the transaction                                      23 September 2022

 f)   Place of the transaction                                     London Stock Exchange, AIM

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHLQLFLLKLLBBZ